Mr. Frisoli has recently represented:
- Keryx Biopharmaceuticals, Inc. in its merger with Akebia Therapeutics, Inc., with an implied pro forma equity value of approximately $1.3 billion.
- Unum Therapeutics and Neon Therapeutics on their initial public offerings.
- KIND LLC, in assistance with equity compensation matters following its strategic partnership with Mars.
- Several private equity and venture capital firms in their acquisition and sale of portfolio companies.
Mr. Frisoli is a member of the Massachusetts and Boston Bar Associations.